The National Lipid Association Scientific Sessions will be held Thursday to Sunday and will spotlight emerging areas of research such as “cardio-rheumatology,” a renewed push to reinstate LDL as a health system quality metric and more. Christie M. Ballantyne, MD, FACC, FACP, FAHA, FNLA, chief of the section of cardiovascular research and professor of medicine at Baylor College of
- Plozasiran significantly lowered triglyceride levels with commensurate reductions in APOC3, non-HDL-C, and remnant cholesterol
- Data presented at European Atherosclerosis Society 92nd Congress.
Promising results for hyperlipidemia treatment reduce risk of cardiovascular events medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
Phase 2b study results show that investigational plozasiran significantly reduced triglyceride-rich lipoproteins in patients with mixed hyperlipidemia.